COMMERCIAL NAMES |
Botox®, Botox Cosmetic®, Vistabel®, Vistabex®
|
Dysport®, Reloxin®, Azzalure®
|
Prosigne®, Lantox®
|
Neuronox®
|
COMPANY |
Allergan Inc. |
Medicis Pharmaceutical Corp. |
Lanzhou Institute of Biological Products, China |
Medy-Tox Inc., South Korea |
TYPE |
A |
A |
A |
A |
COUNTRIES |
Worldwide, including United States and Canada |
> 65 countries, including United States and Canada |
> 10 countries including China, not in the United States or Canada |
South Korea, India, South America, not in the United States or Canada |
ACTIVE SUBSTANCE (MOLECULAR WEIGHT) |
BTX-A complex (900 kD) |
BTX-A complex (500–900 kD) |
BTX-A (900 kD) |
BTX-A (940 kD) |
STRENGTH (BTX-A: PRODUCT) |
1:1 |
1:2–1:4 |
|
|
INDICATIONS |
Blepharospasm, cervical dystonia, glabellar lines, hyperhidrosis, chronic migraine, urinary incontinence, etc. |
Blepharospasm, cervical dystonia, glabellar lines |
Blepharospasm, cervical dystonia, glabellar lines, hyperhidrosis |
Blepharospam |
FDA APPROVAL |
Botox®: cervical dystonia, severe primary axillary hyperhidrosis, blepharo- spasm, neurogenic detrusor overactivity (urinary incontinence), chronic migraine, upper limb spasticity Botox Cosmetic®: glabellar lines (moderate to severe) |
Cervical dystonia, glabellar lines (moderate to severe) |
None |
None |
MODE OF ACTION |
SNAP-25 |
SNAP-25 |
SNAP-25 |
SNAP-25 |
PHARMACEUTICAL FORM |
Powder |
Powder |
Powder |
Powder |
UNITS/VIAL |
100 or 200 |
300 or 500 |
50 or 100 |
100 |
VOLUME |
1.25 or 2.5mL, 10mL max |
2.5mL to 5mL max |
|
|
RECONSTITUTION |
0.9% NaCl |
0.9% NaCl |
|
|
EXCIPIENTS |
Human serum albumin, NaCl |
Human serum albumin, lac- tose |
Gelatin, dextran, sucrose |
Human serum albumin, NaCl |
STORAGE BEFORE DILUTION |
2–8°C or < -5°C |
2–8°C |
2–8°C |
2–8°C |
STORAGE AFTER DILUTION |
24 hours/2–8°C |
4 hours/2–8°C |
4 hours/2–8°C |
4 hours/2–8°C |